Search | MakeMyFriends

Pratiksha Dhote added blog Health
2026-04-16 09:29:28 -

GLP‑1 agonists: miracle drugs for metabolic syndrome, but who can afford them?
Ozempic, Wegovy, Mounjaro — you've heard the hype. These GLP‑1 agonists were diabetes drugs, but they cause dramatic weight loss and improve every component of metabolic syndrome. The metabolic syndrome market research study shows that the pharmaceutical segment is the largest by far, driven by these blockbusters. But here's the rub: they cost $1,000+ per month, and many...

0 Comments 0 Shares 25 Views 0 Reviews

Please log in to like, share and comment!
Pratiksha Dhote added blog Health
2026-04-14 11:24:11 -

GLP‑1 agonists: miracle drugs for metabolic syndrome, but who can afford them?
Ozempic, Wegovy, Mounjaro — you've heard the hype. These GLP‑1 agonists were diabetes drugs, but they cause dramatic weight loss and improve every component of metabolic syndrome. The metabolic syndrome market research study shows that the pharmaceutical segment is the largest by far, driven by these blockbusters. But here's the rub: they cost $1,000+ per month, and many...

0 Comments 0 Shares 28 Views 0 Reviews

Please log in to like, share and comment!
Vanshika Swami added blog Health
2026-04-16 09:04:54 -

Global Cardiometabolic Diseases Market by 2034: Growth Outlook, Key Players & U.S. Regional Analysis
The global cardiometabolic diseases market is witnessing steady expansion driven by the rising prevalence of interconnected chronic conditions such as cardiovascular disease, type 2 diabetes, obesity, and hypertension. According to industry estimates, the market size is valued at approximately US$ 109.28 billion in 2025 and is projected to reach US$ 155.56 billion by 2034, growing at a CAGR of...

0 Comments 0 Shares 41 Views 0 Reviews

Please log in to like, share and comment!